Table 1.
Characteristic | Radiation Therapy Alone (N = 126) | Radiation Therapy plus PCV (N = 125) |
---|---|---|
Median age — yr | 40 | 41 |
Sex — no. (%) | ||
Male | 77 (61) | 65 (52) |
Female | 49 (39) | 60 (48) |
Race or ethnic group — no. (%)† | ||
White | 116 (92) | 111 (89) |
Hispanic | 5 (4) | 6 (5) |
Black | 5 (4) | 5 (4) |
Asian, American Indian, or Alaska Native | 0 | 3 (2) |
Karnofsky performance-status score — no. (%)‡ | ||
60–80 | 33 (26) | 31 (25) |
90 or 100 | 93 (74) | 94 (75) |
Neurologic function — no. (%) | ||
No symptoms | 49 (39) | 62 (50) |
Minor symptoms | 67 (53) | 49 (39) |
Moderate symptoms and fully active | 5 (4) | 10 (8) |
Moderate symptoms and not fully active | 5 (4) | 4 (3) |
Extent of surgery — no. (%) | ||
Biopsy | 59 (47) | 60 (48) |
Partial resection | 56 (44) | 51 (41) |
Total resection | 11 (9) | 14 (11) |
Histologic findings — no. (%) | ||
Astrocytoma | 29 (23) | 36 (29) |
Oligodendroglioma | 57 (45) | 50 (40) |
Oligoastrocytoma | ||
Astrocytoma features dominant | 19 (15) | 19 (15) |
Astrocytoma features equivalent to oligodendroglioma features | 5 (4) | 1 (1) |
Oligodendroglioma features dominant | 16 (13) | 19 (15) |
IDH1 R132H mutation — no./total no. (%) | ||
Present | 35/57 (61) | 36/56 (64) |
Absent | 22/57 (39) | 20/56 (36) |
MMSE score — no. (%)§ | ||
<27 | 11 (9) | 17 (14) |
27–30 | 111 (88) | 99 (79) |
Not completed | 4 (3) | 9 (7) |
There were no significant between-group differences at baseline. IDH1 denotes isocitrate dehydrogenase 1 gene, and PCV procarbazine, lomustine (also called CCNU), and vincristine.
Race or ethnic group was self-reported.
Karnofsky performance-status scores range from 0 to 100, with lower numbers indicating greater disability.
Scores on the Mini–Mental State Examination (MMSE) range from 0 to 30, with lower scores indicating poor cognitive performance. Scores of 27 to 30 are considered to be in the normal range; a score of less than 27 is considered to be abnormal.